230 related articles for article (PubMed ID: 26098776)
1. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation.
Kimura T; Sugaya M; Oka T; Blauvelt A; Okochi H; Sato S
Oncotarget; 2015 Jul; 6(20):18081-93. PubMed ID: 26098776
[TBL] [Abstract][Full Text] [Related]
2. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.
Lund AW; Duraes FV; Hirosue S; Raghavan VR; Nembrini C; Thomas SN; Issa A; Hugues S; Swartz MA
Cell Rep; 2012 Mar; 1(3):191-9. PubMed ID: 22832193
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node.
Carrière V; Colisson R; Jiguet-Jiglaire C; Bellard E; Bouche G; Al Saati T; Amalric F; Girard JP; M'Rini C
Cancer Res; 2005 Dec; 65(24):11639-48. PubMed ID: 16357175
[TBL] [Abstract][Full Text] [Related]
5. Myoinjury transiently activates muscle antigen-specific CD8+ T cells in lymph nodes in a mouse model.
Liao H; Franck E; Fréret M; Adriouch S; Baba-Amer Y; Authier FJ; Boyer O; Gherardi RK
Arthritis Rheum; 2012 Oct; 64(10):3441-51. PubMed ID: 22674045
[TBL] [Abstract][Full Text] [Related]
6. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigens are constitutively presented in the draining lymph nodes.
Marzo AL; Lake RA; Lo D; Sherman L; McWilliam A; Nelson D; Robinson BW; Scott B
J Immunol; 1999 May; 162(10):5838-45. PubMed ID: 10229818
[TBL] [Abstract][Full Text] [Related]
8. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
9. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
10. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
12. CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.
Matsuo K; Itoh T; Koyama A; Imamura R; Kawai S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
Cancer Lett; 2016 Aug; 378(1):16-22. PubMed ID: 27132989
[TBL] [Abstract][Full Text] [Related]
13. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
14. Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma.
Nakasone Y; Fujimoto M; Matsushita T; Hamaguchi Y; Huu DL; Yanaba M; Sato S; Takehara K; Hasegawa M
Am J Pathol; 2012 Jan; 180(1):365-74. PubMed ID: 22037251
[TBL] [Abstract][Full Text] [Related]
15. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
[TBL] [Abstract][Full Text] [Related]
16. Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C.
Baey C; Yang J; Ronchese F; Harper JL
PLoS One; 2018; 13(11):e0206827. PubMed ID: 30383838
[TBL] [Abstract][Full Text] [Related]
17. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
18. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
19. Lymph node tumor metastases: more susceptible than primary tumors to CD8(+) T-cell immune destruction.
Contassot E; Preynat-Seauve O; French L; Huard B
Trends Immunol; 2009 Dec; 30(12):569-73. PubMed ID: 19837632
[TBL] [Abstract][Full Text] [Related]
20. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
